Sedentary lifestyles, cigarette smoking addiction, and chemical pollutants drive the bronchitis treatment market. World Health Organization (WHO) guidelines, stringent regulations for pollutant emission control, and adherence to various international protocols such as the Montreal Protocol and World Bank-MDG are expected to boost the overall bronchitis treatment market.
Chronic bronchitis is defined as bronchial inflammation that lasts for more than three months in a row for two years. The bronchi are the tubes that transport air to the lungs. Bronchitis is characterized by a persistent cough with mucus expectoration, headache, nasal congestion, sore throat, and fatigue. Irritants, chemicals, air pollution, and smoke are all risk factors for bronchitis.
Bronchitis is classified into two types: acute (short-term) and chronic (long-term) (long-term). Acute bronchitis is typically caused by a viral infection and lasts 10 to 15 days. The first line of treatment for acute bronchitis is symptomatic therapy; however, if symptoms persist, antimicrobial therapy is recommended. Antibacterial medications, such as clarithromycin or azithromycin, are commonly used.
Bronchodilators and steroids are used to treat chronic bronchitis. Bronchodilators such as albuterol (Ventolin, Proventil, Vospire, ProAir), metaproterenol (Alupent), formoterol, and salmeterol relax the smooth muscles of the bronchi, allowing the inner wall to expand for better airway passage.
Furthermore, steroids such as prednisone and methylprednisolone are used to help reduce inflammation and, as a result, mucus secretion. Antibiotics are sometimes given, especially when there is an exacerbation of chronic bronchitis caused by bacterial infection. PDE4 inhibitors are also being studied for their potential use in the treatment of chronic bronchitis. Novartis, for example, received FDA approval for Arcapta Neohaler.
Bronchitis Treatment Market: OverviewA significant increase in respiratory disorders, combined with an alarming rise in chemical pollutants, will drive the demand for effective bronchitis treatment. During the forecast period, the market is expected to grow at a healthy rate.
Bronchitis Treatment Market: Region-wise outlook during the forecast period, the global Bronchitis Treatment Market is expected to grow at a significant CAGR. The global Bronchitis Treatment Market is divided into seven key regions based on geographic regions: North America, South America, Eastern Europe, Western Europe, and Asia Pacific (excluding Japan, Japan, and the Middle East and Africa) are the countries involved.
North America dominates the global Bronchitis Treatment Market due to high healthcare awareness and well-developed healthcare infrastructure. With its new regulations in the major economies, Europe ranks second in this market. Asia Pacific is expected to grow the fastest and gain the most market share during the forecast period.
Bronchitis Treatment Market: Key PlayersMajor players in this market include
- Pfizer Inc.
- GlaxoSmithKline Pharmaceuticals Limited
- Sanofi Aventis
- Boehringer Ingelheim
- Dr. Reddy’s Laboratories Ltd
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology, and applications.
Bronchitis Treatment Market: SegmentationBronchitis Treatment Market further segmented into the following types
By Treatment:
- Drugs
- Oxygen therapy
By Class of Drugs:
- Antibiotics
- Bronchodilators
- Mucolytics
- Anti-inflammatory Drugs
By End User
- Hospitals
- Clinics
- Drug stores
For Critical Insights, Get a Sample Copy
